Increased circulating endothelial progenitor cells and improved short-term outcomes in acute non-cardioembolic stroke after hyperbaric oxygen therapy

Journal of Translational Medicine

Sheng-Yuan Hsiao¹  Chih-Min Su¹  Chia-Te Kung¹  Chen-Yu Chen²  Re-Wen Wu²  Mel S. Lee²  Ben-Chung Cheng³  Chih-Cheng Huang⁴  Yun-Ru Lai⁴  Cheng-Hsien Lu⁴  Nai-Wen Tsai⁴  Hung-Chen Wang⁵  Mei-Chi Hsu⁶  Yi-Fang Chiang⁷  Wei-Che Lin⁸  Yu-Jih Su⁹ 

[1] Department of Emergency Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Hyperbaric Oxygen Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Nephrology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Nursing, I-Shou University;Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;Department of Rheumatology, Allergy and Immunology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine;

关键词: Endothelial progenitor cells;    Hyperbaric oxygen therapy;    Non-cardioembolic stroke;    National Institutes of Health Stroke Scale;    Barthel index;    Modified Rankin Scale;   

DOI  :  10.1186/s12967-018-1629-x

来源: DOAJ

【 摘 要 】

Abstract Background Acute ischemic stroke is a leading cause of mortality and long-term disability, and profiles of endothelial progenitor cells (EPCs) reflect the degree of endothelial impairment. This study tested the hypothesis that hyperbaric oxygen therapy (HBOT) both improves the clinical short-term outcomes and increases the number of circulating EPCs and antioxidant capacity. Methods The numbers of circulating EPCs [CD133+/CD34+ (%), KDR+/CD34+ (%)], biomarkers for oxidative stress (thiols and thiobarbituric acid-reactive substances), and clinical scores (National Institutes of Health Stroke Scale [NIHSS], Barthel index [BI], and modified Rankin Scale [MRS]) were prospectively evaluated in 25 patients with acute non-cardioembolic stroke under HBOT at two time points (pre- and post-HBOT). The biomarkers and clinical scores were compared with those of 25 age- and sex-matched disease controls. Results The numbers of KDR+/CD34+ (%) in the HBOT group following HBOT increased significantly, whereas the numbers of CD133+/CD34+ (%) also showed a tendency to increase without statistical significance. The mean high-sensitivity C-reactive protein levels showed significant decrease post-HBOT follow-up in the HBOT group. The changes in KDR+/CD34+EPC (%) numbers were positively correlated with changes in clinical outcomes scores (BI, NIHSS, and MRS) in the HBOT group. Conclusions Based on the results of our study, HBOT can both improve short-term clinical outcomes and increase the number of circulating EPCs in patients with acute non-cardioembolic stroke.

【 授权许可】

Unknown